4D Molecular Therapeutics Share Holder Equity 2020-2024 | FDMT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

4D Molecular Therapeutics share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

4D Molecular Therapeutics share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$78.6B
Takeda Pharmaceutical (TAK)	$44.1B
Merck (MKKGY)	$21.2B
Astellas Pharma (ALPMY)	$20.4B
Sandoz Group AG (SDZNY)	$19.7B
United Therapeutics (UTHR)	$18B
Summit Therapeutics (SMMT)	$15.6B
Neurocrine Biosciences (NBIX)	$12.6B
Shionogi (SGIOY)	$12.5B
Catalent (CTLT)	$10.9B
Madrigal Pharmaceuticals (MDGL)	$7.7B
Jazz Pharmaceuticals (JAZZ)	$7.4B
Orion OYJ (ORINY)	$6.8B
Ionis Pharmaceuticals (IONS)	$6.1B
Corcept Therapeutics (CORT)	$5.7B
Crinetics Pharmaceuticals (CRNX)	$4.8B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$2.9B
Catalyst Pharmaceuticals (CPRX)	$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.7B
Soleno Therapeutics (SLNO)	$2.5B
NewAmsterdam Pharma (NAMS)	$2B
Recursion Pharmaceuticals (RXRX)	$1.9B
Centessa Pharmaceuticals (CNTA)	$1.8B
Harrow (HROW)	$1.8B
Ocular Therapeutix (OCUL)	$1.7B
Xencor (XNCR)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
ARS Pharmaceuticals (SPRY)	$1.6B